Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.03
+0.24 (0.11%)
AAPL  262.89
-1.46 (-0.55%)
AMD  201.29
+1.17 (0.59%)
BAC  52.62
-0.73 (-1.38%)
GOOG  303.55
-0.39 (-0.13%)
META  643.41
+0.19 (0.03%)
MSFT  398.64
-0.96 (-0.24%)
NVDA  186.59
-1.39 (-0.74%)
ORCL  157.73
+1.56 (1.00%)
TSLA  412.81
+1.50 (0.36%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.